Aclaris Therapeutics, Inc.
ACRS evidence brief
What we can confirm
- BioSniper Score:
- 5.5 / 10
- Market Cap:
- $873.6M
- Lead Asset:
- ATI-2138 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ACRS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACRS
Aclaris Therapeutics, Inc. (ACRS) is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases, with a pipeline including bispecific antibodies and oral inhibitors.
Key risk: Early-stage pipeline
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 4 clinical trials · 1 catalyst for Aclaris Therapeutics, Inc..
Aclaris Therapeutics, Inc. (ACRS) is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases, with a pipeline including bispecific antibodies and oral inhibitors.
- Cash & equivalents of $19.2M as of 2026-06-30 [sec].
- Total revenue of $1.6M and net income of -$21.5M as of 2026-06-30 [sec].
- Shareholders' equity of $124.6M as of 2026-06-30 [sec].
- Positive full top line results from Phase 1a SAD/MAD trial of ATI-052 reported in August 2026 [news · published 2026-08-06].
- Cash runway expected to fund operations through the end of 2028 [news · published 2026-08-06].
What works
- Strong cash runway expected to fund operations through the end of 2028, providing financial stability for pipeline development [news · published 2026-08-06].
- Positive Phase 1a results for ATI-052, a potential best-in-class bispecific antibody, demonstrating strong safety, tolerability, and extended pharmacokinetics [news · published 2026-01-13].
- Positive Phase 2a results for ATI-2138, an ITK/JAK3 inhibitor, confirming tolerability and showing a strong efficacy signal [news · published 2025-08-07].
What to weigh
- Net loss of $21.5M as of 2026-06-30, indicating ongoing operational losses [sec].
- Total revenue of only $1.6M as of 2026-06-30, reflecting minimal product sales or licensing income [sec].
- All pipeline candidates are in early clinical stages (Phase 1 or 2), with no approved products generating revenue [pipeline].
From the filings
Quoted directly from source documents.
Cash position and financial runway
“Strong Cash Runway Expected to Enable Development of Pipeline Through the End of 2028”
News · August 6, 2026
Positive Phase 1a results for ATI-052
“positive Phase 1a interim results which demonstrated a strong safety and tolerability profile, extended pharmacokinetics, and concentration-dependent pharm”
News · January 13, 2026
Positive Phase 2a results for ATI-2138
“Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate ITK as Therapeutic Target”
News · August 7, 2025
Catalyst timeline
- 2035-07-04 · Patent_Expiry · HYDROGEN PEROXIDE — Patent_Expiry: NDA209305 — Patent expiry for a hydrogen peroxide product; no direct impact on current pipeline but may affect related intellectual property.
Risks & what to watch (3)›
Key risks
- Early-stage pipeline — All candidates are in Phase 1 or 2, with no approved products; clinical failure could halt revenue generation [pipeline].
- Negative net income — Net loss of $21.5M as of 2026-06-30, indicating ongoing cash burn without offsetting revenue [sec].
- Low revenue base — Total revenue of $1.6M as of 2026-06-30, insufficient to cover operating expenses [sec].
What to watch
- Top line results from Phase 1b proof-of-concept trial of ATI-052 in atopic dermatitis, expected in 2026 [news · published 2026-08-06].
- Top line results from Phase 2 trial of Bosakitug (ATI-045) in atopic dermatitis, expected in 2026 [news · published 2026-08-06].
- Initiation of Phase 2 trial of ATI-2138 in an additional indication, expected in first half of 2026 [news · published 2025-11-06].
- Cash runway sustainability through end of 2028, given ongoing net losses [news · published 2026-08-06].
Sources: Catalysts · News · Pipeline · Generated October 2, 2026 · How we verify sources →
Run Aclaris Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aclaris Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.44 · 0% dilution
Lead: Phase 2
3 candidates
1 upcoming, next in ~3185d
0 buys · 1 sell (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 6.5%
- Days to cover
- 5.5
- Shares short
- 7,889,202
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ACRS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aclaris Therapeutics, Inc.?
Aclaris Therapeutics, Inc. (ACRS) is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases, with a pipeline including bispecific antibodies and oral inhibitors.
What is Aclaris Therapeutics, Inc.'s lead drug candidate?
Aclaris Therapeutics, Inc.'s most advanced tracked candidate is ATI-2138 (Phase 2) for Atopic Dermatitis.
What is Aclaris Therapeutics, Inc.'s next catalyst?
Aclaris Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA209305" — expected July 4, 2035.
Who is the CEO of Aclaris Therapeutics, Inc.?
Dr. Neal S. Walker D.O., M.D. is the chief executive officer of Aclaris Therapeutics, Inc. (ACRS).
Where is Aclaris Therapeutics, Inc. headquartered?
Aclaris Therapeutics, Inc. (ACRS) is headquartered in Wayne, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.